These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 30216091)

  • 1. Pharmacokinetics of anticoagulants apixaban, dabigatran, edoxaban and rivaroxaban in elderly Japanese patients with atrial fibrillation treated in one general hospital.
    Yamazaki-Nishioka M; Kogiku M; Noda M; Endo S; Takekawa M; Kishi H; Ota M; Notsu Y; Shimizu M; Yamazaki H
    Xenobiotica; 2019 Sep; 49(9):1001-1006. PubMed ID: 30216091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
    Lip GY; Mitchell SA; Liu X; Liu LZ; Phatak H; Kachroo S; Batson S
    Int J Cardiol; 2016 Feb; 204():88-94. PubMed ID: 26655548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Considerations for Prescribing Target-Specific Oral Anticoagulants in the Setting of Renal Dysfunction or Drug Interactions.
    Pan EY; Sobieraj DM
    Conn Med; 2016 Feb; 80(2):105-11. PubMed ID: 27024982
    [No Abstract]   [Full Text] [Related]  

  • 4. Non-Vitamin K Antagonist Oral Anticoagulants and Factors Influencing the Ischemic and Bleeding Risk in Elderly Patients With Atrial Fibrillation: A Review of Current Evidence.
    Patti G; Haas S
    J Cardiovasc Pharmacol; 2020 Oct; 77(1):11-21. PubMed ID: 33060545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profiles.
    Goto E; Horinaka S; Ishimitsu T; Kato T
    Drug Metab Pharmacokinet; 2020 Feb; 35(1):151-159. PubMed ID: 32007354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative study of hemorrhagic and ischemic complications among anticoagulants in patients undergoing cryoballoon ablation for atrial fibrillation.
    Okishige K; Nakamura T; Aoyagi H; Kawaguchi N; Yamashita M; Kurabayashi M; Suzuki H; Asano M; Shimura T; Yamauchi Y; Sasano T; Hirao K
    J Cardiol; 2017 Jan; 69(1):11-15. PubMed ID: 27160710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.
    Di Lullo L; Ronco C; Cozzolino M; Russo D; Russo L; Di Iorio B; De Pascalis A; Barbera V; Galliani M; Vitaliano E; Campana C; Santoboni F; Bellasi A
    Thromb Res; 2017 Jul; 155():38-47. PubMed ID: 28482261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ninety-day prognosis of patients receiving direct oral anticoagulants in the early phase of non valvular atrial fibrillation-related acute ischemic stroke: The real life evidence.
    Masotti L; Grifoni E; Dei A; Vannucchi V; Moroni F; Spolveri S; Panigada G; Landini G
    Thromb Res; 2018 Dec; 172():165-168. PubMed ID: 30419471
    [No Abstract]   [Full Text] [Related]  

  • 9. Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non-Vitamin K Antagonist Oral Anticoagulants' Administration for Secondary Prevention of Stroke.
    Kanai Y; Oguro H; Tahara N; Matsuda H; Takayoshi H; Mitaki S; Onoda K; Yamaguchi S
    J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):338-345. PubMed ID: 29033229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
    Graff J; Harder S
    Clin Pharmacokinet; 2013 Apr; 52(4):243-54. PubMed ID: 23389892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs.
    Mikus G; Foerster KI; Schaumaeker M; Lehmann ML; Burhenne J; Haefeli WE
    Clin Pharmacokinet; 2019 Sep; 58(9):1155-1163. PubMed ID: 30828771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 13. Impact of new oral anticoagulants on gastrointestinal bleeding in atrial fibrillation: A meta-analysis of interventional trials.
    Loffredo L; Perri L; Violi F
    Dig Liver Dis; 2015 May; 47(5):429-31. PubMed ID: 25732432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Facing real-life with direct oral anticoagulants in patients with nonvalvular atrial fibrillation: outcomes from the first observational and prospective study in a Spanish population.
    Cerdá M; Cerezo-Manchado JJ; Johansson E; Martínez F; Fernández M; Varela A; Rodríguez S; Bosch F; Santamaría A
    J Comp Eff Res; 2019 Feb; 8(3):165-178. PubMed ID: 30654626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of rivaroxaban in the treatment of nonvalvular atrial fibrillation.
    Norby FL; Alonso A
    J Comp Eff Res; 2017 Sep; 6(6):549-560. PubMed ID: 28737102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Oral Anticoagulants: What Prescribers Should Know; Differences and Similarities between Warfarin and "New Agents" (Dabigatran, Rivaroxaban, Apixaban, Edoxaban) - Review of Indications, Contraindications and Safety of Use.
    Petrasko M; Raizada A; Petraskova T
    S D Med; 2016 Aug; 69(8):363-369. PubMed ID: 28806005
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of direct oral anticoagulants on lupus anticoagulant assays in a real-life setting.
    Antovic A; Norberg EM; Berndtsson M; Rasmuson A; Malmström RE; Skeppholm M; Antovic J
    Thromb Haemost; 2017 Aug; 117(9):1700-1704. PubMed ID: 28640321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Not Available].
    Simeon L; Wuillemin WA
    Ther Umsch; 2016; 73(10):561-566. PubMed ID: 28045358
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacogenetics of novel oral anticoagulants: a review of identified gene variants & future perspectives.
    Ašić A; Marjanović D; Mirat J; Primorac D
    Per Med; 2018 May; 15(3):209-221. PubMed ID: 29767545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of an UHPLC-UV-Method for Quantification of Direct Oral Anticoagulants: Apixaban, Rivaroxaban, Dabigatran, and its Prodrug Dabigatran Etexilate in Human Serum.
    Boehr S; Haen E
    Ther Drug Monit; 2017 Feb; 39(1):66-76. PubMed ID: 27861316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.